Utilizing a subcutaneous tumor model in mice, it has been confirmed that IBA reverses the significant induction of CD8+ T lymphocyte infiltration in CRC tissues by anti‐PD‐L1 antibody treatment and activates the suppression of IFNγ and granzyme B expression, demonstrating inhibition of CRC cell proliferation with notable therapeutic effects, consistent with previous studies [13]. This evidence concerns the gene CD8A and neoplasm.